Dimensional Fund Advisors LP Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Dimensional Fund Advisors LP lessened its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 25.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,642 shares of the company’s stock after selling 11,869 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Vaxcyte were worth $2,691,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Parkman Healthcare Partners LLC raised its position in Vaxcyte by 12.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 267,594 shares of the company’s stock valued at $16,805,000 after purchasing an additional 29,462 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Vaxcyte by 12.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 481,119 shares of the company’s stock worth $30,214,000 after acquiring an additional 52,005 shares during the period. Vanguard Group Inc. raised its stake in shares of Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after acquiring an additional 168,125 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vaxcyte by 25.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock valued at $439,000 after purchasing an additional 1,411 shares during the period. Finally, Banque Cantonale Vaudoise grew its stake in Vaxcyte by 96.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after purchasing an additional 582 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Price Performance

NASDAQ PCVX opened at $111.60 on Friday. The company has a fifty day moving average of $96.95 and a two-hundred day moving average of $80.26. The company has a market capitalization of $12.14 billion, a PE ratio of -26.14 and a beta of 0.99. Vaxcyte, Inc. has a 1 year low of $44.20 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same period last year, the firm earned ($0.70) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Insider Activity

In related news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the completion of the sale, the chief executive officer now owns 478,888 shares in the company, valued at $40,351,102.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Elvia Cowan sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at $1,081,455. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the completion of the sale, the chief executive officer now owns 478,888 shares in the company, valued at approximately $40,351,102.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,098 shares of company stock valued at $7,429,653. 3.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Leerink Partners lifted their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Mizuho raised their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Bank of America boosted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, Needham & Company LLC raised their price target on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.